Literature DB >> 16160741

Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.

Stefania Bonadonna1, Gherardo Mazziotti, Monica Nuzzo, Antonio Bianchi, Alessandra Fusco, Laura De Marinis, Andrea Giustina.   

Abstract

UNLABELLED: This cross-sectional study shows that high numbers of postmenopausal women with acromegaly develop vertebral fractures in relation to the activity of disease. In patients with active acromegaly, vertebral fractures occur even in presence of normal BMD, whereas in patients with controlled acromegaly, vertebral fractures are always accompanied by a pathological BMD.
INTRODUCTION: We studied the frequency of radiological vertebral fractures in a cohort of postmenopausal women with active or controlled acromegaly.
MATERIALS AND METHODS: Thirty-six postmenopausal acromegalic patients (15 with active and 21 with controlled disease) were evaluated for BMD, bone metabolism (serum 25-hydroxyvitamin D, PTH, bone-specific alkaline phosphatase [BSALP], and urinary deoxypyridinoline [Dpd]), and vertebral quantitative morphometry. Thirty-six nonacromegalic postmenopausal women, matched for age, were selected among the patients consulting the Bone Center as a control group for BMD evaluation and vertebral quantitative morphometry.
RESULTS: Vertebral fractures were shown in 19 patients (52.8%) and 11 controls (30.6%; chi2: 3.7; p=0.06). Fractured acromegalic women were older and had higher serum IGF-1, Dpd, and BSALP and lower T score and serum vitamin D values compared with nonfractured patients. Moreover, the fractured women had a longer diagnosis and were in the postmenopausal period for a longer period than the nonfractured women. The fracture rate was significantly higher in active than in controlled acromegaly (80% versus 33.3%; chi2: 7.6; p=0.008). The patients with active acromegaly who fractured (12 cases) had significantly higher serum IGF-1 values (356 ng/ml; range: 212-950 versus 120 ng/ml; range: 84-217; p<0.001) and T scores (-1.3 SD, range: -2.9 to +1.3 versus -2.7 SD, range: -3.4 to -1.5, p=0.04) compared with the fractured women whose disease was controlled (7 cases). All fractured women with controlled acromegaly had T scores<-1.0 SD (57.1% of them had osteoporosis, and 42.9% were osteopenic). In contrast, 41.7% of women whose fractures were associated with active disease had a normal T score (>-1.0 SD), whereas osteopenia and osteoporosis were found only in 33.3% and 25.0% of them, respectively.
CONCLUSIONS: This cross-sectional study shows that high numbers of postmenopausal women with acromegaly develop vertebral fractures in relation to the activity of disease. Furthermore, our study shows that, in patients with active acromegaly, vertebral fractures occur even in the presence of normal BMD, whereas in patients with controlled acromegaly, vertebral fractures are always accompanied by a pathological BMD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160741     DOI: 10.1359/JBMR.050603

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  46 in total

Review 1.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

2.  The acromegalic spine: fractures, deformities and spinopelvic balance.

Authors:  Bruno de Azevedo Oliveira; Bruna Araujo; Tainá Mafalda Dos Santos; Bárbara Roberta Ongaratti; Carolina Garcia Soares Leães Rech; Nelson Pires Ferreira; Júlia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 3.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 4.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

5.  Optimal use of pegvisomant in acromegaly: are we getting there?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2014-10-28       Impact factor: 3.633

6.  Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome.

Authors:  Anna Maria Formenti; Mauro Doga; Stefano Frara; Marco Ritelli; Marina Colombi; Giuseppe Banfi; Andrea Giustina
Journal:  Endocrine       Date:  2018-12-15       Impact factor: 3.633

7.  Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Authors:  L Dalle Carbonare; V Micheletti; E Cosaro; M T Valenti; M Mottes; G Francia; M V Davì
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

8.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 9.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

10.  Is every joint symptom related to acromegaly?

Authors:  Gonca Örük; Figen Tarhan; Mehmet Argın; Mustafa Özmen
Journal:  Endocrine       Date:  2012-08-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.